高级检索

维持性血液透析患者成纤维细胞生长因子23与心血管病变的临床研究

陈蕊, 邢昌赢, 徐道亮, 魏丛军, 刘昌华, 李冰, 陈勇

陈蕊, 邢昌赢, 徐道亮, 魏丛军, 刘昌华, 李冰, 陈勇. 维持性血液透析患者成纤维细胞生长因子23与心血管病变的临床研究[J]. 实用临床医药杂志, 2010, (15): 9-12,16. DOI: 10.3969/j.issn.1672-2353.2010.15.003
引用本文: 陈蕊, 邢昌赢, 徐道亮, 魏丛军, 刘昌华, 李冰, 陈勇. 维持性血液透析患者成纤维细胞生长因子23与心血管病变的临床研究[J]. 实用临床医药杂志, 2010, (15): 9-12,16. DOI: 10.3969/j.issn.1672-2353.2010.15.003
shu
CHEN Rui, XING Chang-ying, XU Dao-liang, WEI Cong-jun, LIU Chang-hua, LI Bin, CHEN Yong. Clinical Research on Relationship between Serum Fibroblast Growth Factor 23 and Cardiovascular Disease in Maintenance Hemodialysis Patients[J]. Journal of Clinical Medicine in Practice, 2010, (15): 9-12,16. DOI: 10.3969/j.issn.1672-2353.2010.15.003
Citation: CHEN Rui, XING Chang-ying, XU Dao-liang, WEI Cong-jun, LIU Chang-hua, LI Bin, CHEN Yong. Clinical Research on Relationship between Serum Fibroblast Growth Factor 23 and Cardiovascular Disease in Maintenance Hemodialysis Patients[J]. Journal of Clinical Medicine in Practice, 2010, (15): 9-12,16. DOI: 10.3969/j.issn.1672-2353.2010.15.003
shu

维持性血液透析患者成纤维细胞生长因子23与心血管病变的临床研究

  • 1.

    南京医科大学,江苏,南京,210009;

  • 2.

    扬州大学第一临床医学院,江苏,扬州,225009;

  • 3.

    南京医科大学附属第一医院,肾内科,江苏,南京,210029;

  • 4.

    扬州大学第一临床医学院,江苏,扬州,225009

详细信息

  • 中图分类号: R459.5

Clinical Research on Relationship between Serum Fibroblast Growth Factor 23 and Cardiovascular Disease in Maintenance Hemodialysis Patients

摘要

    摘要
  • 摘要: 目的 分析维持性血液透析(MHD)患者血清成纤维细胞生长因子23(FGF-23)与心血管病变的关系,探讨FGF-23对心血管疾病的影响机制.方法 选取本院MHD患者50例,应用夹心酶联免疫吸附法(ELISA法)检测FGF-23, 同时行血液生化指标、彩色多普勒超声心动图、颈部血管超声检查.结果 MHD患者血清FGF-23水平较健康对照组显著升高(P<0.01).相关性分析显示,MHD患者血清FGF-23与血清肌酐、磷、全段甲状旁腺激(iPTH)呈正相关(P<0.01), 与1, 25-二羟维生素D3[1, 25-(OH)2VitD]呈负相关(P<0.01), 与血清钙无关(P>0.05).心血管病变组血清FGF-23显著高于非心血管病变组(P<0.01).逐步多元回归分析显示FGF-23是颈总动脉内-中膜厚度(β=0.189, P<0.01)的独立危险因素.结论 MHD患者FGF-23水平明显升高,提示其是重要的磷调节因子.FGF23与MHD患者心血管病变的发生发展密切相关.
    • HTML全文
    • 参考文献(16)
  • Parekh RS, Carroll CE, Wolfe RA. Cardiovarscular death in children and young adults with end-stage kidney disease [J]. Journal of Pediatrics, 2002.191.
    Samak MJ, Levey AS, Schoolwenh AC. Kidney disease as a risk factor for development of cardiovascular disease:A statement fiom the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, cnnical cardiology, and epidemiology and prevention [J]. Hypertension, 2003.1050.
    Kenneth B, Jonsson. The ro1e of fibroblast growth factor 23 in renal disease [J]. Nephrol Dialys Transplant, 2005.479.
    Fukagawa M, Kazama JJ. FGF23:its role in renal bone disease [J]. Pediatric Nephrology, 2006.1802.
    Capomolla S, Febo O, Gnemmi M. Beta-blockade therapy in chronic heart failure:diastolic function and mitral regurgitation improvement by carvedilol [J]. American Heart Journal, 2000(4):596.
    Ganesh SK, Stack AG, Levin NW. Association of elevated serum PO(4).Cax PO(4)product.And parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients [J]. Journal of the American Society of Nephrology, 2001.2131.
    Block GA, Klassen PS, Lazarus JM. Mineral metabolism, and morbidity in maintenance hemodialysis [J]. Journal of the American Society of Nephrology, 2004.2208.
    Gutierrez O, lsakova T, Rhee E. Fibroblast growth factor 23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in Chronic kidney disease [J]. Journal of the American Society of Nephrology, 2005.2205.
    Stephen G, Rostand Tilman B. Drueke parathyroid hormone, Vitamin D, and cardiovascular disease in CRF [J]. Kidney International, 1999.383.
    Go AS, Chertow GM, Fan D. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization [J]. New England Journal of Medicine, 2004, (13):1296.
    Kobayashi K, Imanishi Y, Miyauchi A. Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism [J]. European Journal of Endocrinology, 2006, (1):93.
    Imanishi Y, Inaba M, Nakatsuka K. FGF-23 inpatients with end-stage renal disease on hemodialysis [J]. Kidney International, 2004.1943.
    Khachigian LM. Early growth response-1 in cardiovascular pathobiology [J]. Circulation Research, 2006.186.
    Mehrotra RJ. Disordered mineral metabolism and vascular calcification in nondialyzed chronic kidney disease patients [J]. Ren Nutr, 2006.100.
    Gutierrez OM, Mannstadt M, Isakova T. Fibroblast growth factor-23 and mortality among patients undergoing hemodialysis [J]. New England Journal of Medicine, 2008.584.
    Jean G, Bresson E, Terrat JC. Peripheral vascular calcification in long-haemodialysis patients:associated factors and survival consequences [J]. Nephrology Dialysis Transplantation, 2009.948.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  141
  • HTML全文浏览量:  25
  • PDF下载量:  12
  • 被引次数: 0
出版历程
  • 发布日期:  2010-11-10

目录

摘要
HTML全文
    参考文献(16)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    © 2020 《实用临床医药杂志》编辑部

    地址：江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室邮编：225009电话：0514-87978917、87978989、87978807

    苏公网安备 32100302010246号

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计